Shionogi acquires IntraBio for $2B to bolster rare disease portfolio

Shionogi, a Japanese pharma, has closed a $2 billion acquisition of U.S.-based IntraBio, a rare disease drug developer. The deal signals strategic consolidation in the rare disease space, with potential implications for Shionogi's pipeline and market positioning. Financial terms and expected synergies remain undisclosed.